CTLA4 and hepatocellular carcinoma: With the approval of immune checkpoint inhibitors (ICIs) (including atezolizumab/bevacizumab, CTLA-4 antibody ipilimumab, and the PD-1 antibody pembrolizumab), the focus of HCC clinical trials has shifted toward immunotherapy [5, 6].